je.st
news
Tag: patients
Cover Story: Culture of care extends beyond patients
2013-11-27 16:52:31| Industrial Machines - Topix.net
Radiology clerks Portia Shepperd and Justine Anderson pick up popcorn balls for their co-workers as a part of Presentation Day at Avera McKennan Hospital.
Tags: care
story
cover
culture
Additional Interim Data for Mercks Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma
2013-11-18 18:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma that showed an estimated overall survival rate of 81 percent at one year across all MK-3475 monotherapy doses evaluated. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
2013-11-15 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Mercks investigational anti-PD-1 immunotherapy. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
presented
Legislation Introduced To Notify Patients and Physicians of Changes to Prescriptions
2013-11-13 06:00:00| Industrial Newsroom - All News for Today
BIO and Pennsylvania Bio commended Pennsylvania Senate Public Health and Welfare Committee for its approval of Senate Bill 405, which would require pharmacist to notify patient, and within 72 hours, the patient's physician of any biologic product substitution. Bill seeks to properly preserve patient access to accurate prescription information, maintains incentives for innovation, and promotes competitive market for biologic therapies. This story is related to the following:Trade Associations
Tags: to
introduced
notify
patients
Patient's Death Halts Cancer Drug Trial
2013-11-07 14:51:25| Biotech - Topix.net
A phase I study of an investigational oral inhibitor of apoptosis antagonist, CUDC-427, has been placed on partial clinical hold by the FDA following the death of a patient who had progressed to liver failure approximately 1 month after the discontinuation of CUDC-427 dosing.
Sites : [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] next »